Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | POLD1 | P28340 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | POLG | P54098 | 2/20 | 0.32 |
| ▸ | DTYMK | P23919 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734506 | 1.00 | FUT5 (0.39) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23734500 | 0.95 | FUT5 (0.38) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23734254 | 0.94 | FUT5 (0.38) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24822985 | 0.94 | FUT5 (0.38) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23734228 | 0.92 | FUT5 (0.37) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23734243 | 0.92 | POLB (0.39) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL26156384 | 0.89 | FUT5 (0.34) | FUT5POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23734403 | 0.88 | POLB (0.45) | POLBP2RY2P2RY6POLA1POLD1 | |
| SCHEMBL24823714 | 0.88 | POLB (0.45) | POLBP2RY2P2RY6POLA1POLD1 | |
| SCHEMBL23734360 | 0.88 | POLG (0.41) | POLBP2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | FUT5 2876/4885POLB 3/4885P2RY2 4626/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | FUT5 3682/4885POLB 18/4885P2RY2 4547/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | FUT5 3762/4885POLB 10/4885P2RY2 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.